[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653469":3},{"organization":4,"outcomesModule":7,"designInfo":20,"detailedDescription":11,"studyPopulation":23,"armGroups":24,"interventions":37,"overallOfficials":11,"centralContacts":11,"locations":48,"responsibleParty":68,"collaborators":11,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":11,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":11,"studyType":83,"phases":11,"briefSummary":84,"conditions":85,"keywords":11,"overallStatus":87,"whyStopped":11,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Université Catholique de Louvain","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":15,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Characterization of the phenotype of peripheral CD19⁺CD11c⁺FCRL5⁺ B lymphocytes in patients with MS",null,"Throughout the entire study, approximately during 40 months",{"measure":14,"description":11,"timeFrame":12},"Characterization of the activity of peripheral CD19⁺CD11c⁺FCRL5⁺ B lymphocytes in patients with MS",[16,18],{"measure":17,"description":11,"timeFrame":12},"Immunological role of CD19⁺CD11c⁺FCRL5⁺ B cells in the pathogenesis of MS.",{"measure":19,"description":11,"timeFrame":12},"Correlations in the participants' clinical, biological, radiological profiles and the immunological characteristics",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":21,"timePerspective":22,"maskingInfo":11},"CASE_CONTROL","PROSPECTIVE","Patients with MS and healthy controls",[25,29,33],{"label":26,"type":11,"description":11,"interventionNames":27},"A group of patients with MS",[28],"Other: A blood test every 6 months for MS patients.",{"label":30,"type":11,"description":11,"interventionNames":31},"A group of healthy volunteers",[32],"Other: A single blood draw for the healthy volunteer",{"label":34,"type":11,"description":11,"interventionNames":35},"A group of volunteers with Sjögren's syndrome",[36],"Other: A single blood draw for the group of volunteers with Sjögren's syndrome",[38,42,45],{"type":6,"name":39,"description":40,"armGroupLabels":41,"otherNames":11},"A blood test every 6 months for MS patients.","A blood test every 6 months for MS patients : Day1, Month 6, Month 12 and Month 24",[26],{"type":6,"name":43,"description":43,"armGroupLabels":44,"otherNames":11},"A single blood draw for the healthy volunteer",[30],{"type":6,"name":46,"description":46,"armGroupLabels":47,"otherNames":11},"A single blood draw for the group of volunteers with Sjögren's syndrome",[34],[49],{"facility":5,"status":11,"city":50,"state":11,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Brussels","1200","Belgium","BE",{"type":55,"coordinates":56},"Point",[57,58],4.34878,50.85045,{"lat":58,"lon":57},[61,66],{"name":62,"role":63,"phone":64,"phoneExt":11,"email":65},"Vincent Van Pesch, MD, PhD","CONTACT","003227641082","vincent.vanpesch@saintluc.uclouvain.be",{"name":62,"role":67,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":69,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100653469","the-role-of-the-fcrl5-protein-in-the-pathophysiology-of-multiple-sclerosis-and-response-to-treatment-100653469",false,"NCT07788573","The Role of the FCRL5 Protein in the Pathophysiology of Multiple Sclerosis and Response to Treatment","Inclusion Criteria:\n\n* For MS patients:\n* Male or female\n* Between 18 and 80 years of age\n* Diagnosed with MS according to the most recent McDonald criteria (2025)\n* Patients who are about to start a new MS treatment or switch treatments\n\nFor healthy volunteers:\n\n* Men or women\n* Ages 18 to 80\n* Healthy volunteers with no neurological conditions or autoimmune diseases\n\nFor participants with Sjögren's syndrome:\n\n* Men or women\n* Ages 18 to 80\n\nExclusion Criteria:\n\n* For MS patients:\n* No recent relapse (during the 3 months prior to study enrollment)\n* Patients treated with corticosteroids (during the 3 months prior to study enrollment)\n* Patients receiving another immunosuppressive therapy unrelated to MS\n* Inability to sign the informed consent form\n\nFor healthy volunteers:\n\nSubjects not receiving immunosuppressive therapy\n\nFor subjects with Sjögren's syndrome:\n\nSubjects not receiving immunosuppressive therapy",true,"ALL","18 Years","80 Years",{"count":81,"type":82},90,"ESTIMATED","OBSERVATIONAL","Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS) and the leading non-traumatic cause of neurological disability in young adults. Historically considered a T-cell-mediated disease, the paradigm for MS has shifted thanks to the efficacy of therapies targeting B cells. The investigators recently identified FCRL5 as a B-cell-specific biomarker that is significantly elevated in the cerebrospinal fluid (CSF) of patients with relapsing-remitting MS and is independently associated with an increased risk of developing new MRI lesions within two years of diagnosis (ref. Deltombe et al., PMID: 41004694). This project aims to further explore FCRL5 as a prognostic biomarker, study the role of FCRL5-expressing B cells in MS pathogenesis and the effects of disease-modifying therapies on these subsets.",[86],"Multiple Sclerosis","NOT_YET_RECRUITING","2026-08-24",{"date":90,"type":91},"2026-08-26","ACTUAL",{"date":93,"type":82},"2026-08",{"date":95,"type":82},"2029-12-31",{"name":5,"class":6},1]